Community - Babraham Research Campus

ABLATUS

Ablatus Therapeutics Ltd, a medical device company, has been founded to develop and commercialise a novel tissue ablation technology to treat the most challenging and often inoperable, solid cancer tumours.

ABZENA PLC

Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena's complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals.

www.abzena.com

ARTIOS PHARMA

Artios Pharma is a biotech specialising in DNA damage response (DDR) as a therapeutic area for novel cancer treatments.

www.artiospharma.com

ATELERIX LIMITED

Atelerix has developed a technology for the storage and transport of viable human cells at room temperature. Both cell- and user-friendly, this overcomes the problems of cryoshipping and opens up the markets for supply of cell-based assays in a ready-to-use format, and biologistics for cell therapy.

www.atelerix.co.uk

Babraham Institute

The Babraham Institute is a world-class research institution, situated at the heart of the Babraham Research Campus.

www.babraham.ac.uk

BenevolentAI

BenevolentAI is the global leader in the development and application of AI for scientific innovation and applies its technology to accelerate the discovery of new medicines. It is the largest private AI company in Europe and one of the world’s top five private AI companies.

benevolent.ai

BICYCLE THERAPEUTICS

Bicycle Therapeutics is a newly formed biotechnology company developing a novel technology for the creation of a new generation of biotherapeutics. The technology is based on the work performed at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Prof. Christian Heinis and Prof. Sir Gregory Winter.

www.bicycletherapeutics.com

BIOSCEPTRE INTERNATIONAL

Biosceptre International is a public, unlisted biotechnology company based in Sydney, Australia and Cambridge, UK. Biosceptre is developing and commercializing antibody technologies to address a wide range of applications in the diagnosis and treatment of cancer.

www.biosceptre.com

CAMBIMUNE

Cambimune is a biotechnology company focused on the research, development and commercialisation of innovative biologicals and other biomedical technologies.

CAMBIVAC LTD

Cambivac® Ltd researches, develops and out-licenses innovative vaccine technologies. It benefits from a close relationship with the University of Cambridge which facilitates its aims of bringing together world class expertise in the fields of traditional virology, modern genomics and molecular vaccine approaches.

CAMBRIDGE PROTEIN ARRAYS LTD

Cambridge Protein Arrays Ltd. is a biotech SME founded in 2010 by Dr Mike Taussig, based on strong academic roots in the fields of protein arrays and protein affinity reagents. Cambridge Protein Arrays Ltd offers products and services in the area of protein microarrays.

www.cambridgeproteinarrays.com

Cambridge Protein Works Ltd

Cambridge Protein Works produce pure proteins for research professionals in industry and academia, saving our customers the considerable effort, time and cost of protein expression and purification.

www.cambridgeproteinworks.com

CAMPHOS THERAPEUTICS

CamPhos Therapeutics is an emerging drug discovery and development company located on the Babraham Research Campus in Cambridge, UK, backed by a leading European investor.

CANCER RESEARCH UK THERAPEUTIC DISCOVERY LABS

Cancer Research UK's Therapeutic Discovery Laboratories (CRUK-TDL), formerly CRT Discovery Laboratories, is the in-house Cancer Research UK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry.

www.discoverylabs.cancerresearchuk.org

CELL GUIDANCE SYSTEM LTD

Cell Guidance Systems offers services and products for life science research. We focus on the field of regenerative medicine. In addition to reagents for stem cell research (growth factors, small molecules, cell culture media) we also offer a growing list of products for exosome research.

www.cellgs.com

Censo Biotechnologies

Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.

www.censobio.com

Closed Loop Medicine

Closed Loop Medicine (CLM) Ltd is a new breed of therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens.

www.closedloopmedicine.com

CRESCENDO BIOLOGICS

Crescendo Biologics is building a pipeline of novel medicines based on its highly innovative VH antibody fragment platform through both in-house development and strategic partnerships.

www.crescendobiologics.com

CYPRALIS LTD

Cypralis is a drug discovery company focused on delivering novel, selective inhibitors of cyclophilins as new treatments for acute and chronic degenerative diseases. Cyclophilin D is a critical member of the Mitochondrial Permeability Transition Pore (MPTP) complex.

www.cypralis.com

DefiniGEN LTD

Providing industrial quantities of human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.

www.definigen.com

DIAGNODUS Ltd

DiagNodus is a biomedical company, the principal direction of which is the development of a new non-invasive approach to colorectal cancer screening based upon introduction of an innovative rapid 'point of care' test.

www.diagnodus.com

Empyrean Therapeutics

Empyrean Therapeutics is focused on developing next generation off-the-shelf cell therapies to enable global and affordable cures for cancer and rare disease.

EPSILON-3 BIO

Epsilon-3 Bio Limited is a preclinical stage company with investment from Index Ventures, Novo Ventures and Imperial Innovations. The company is focused on the efficient development of first in class drug candidates stimulating safe removal of cellular debris.

www.epsilon-3.com

F-STAR BIOTECHNOLOGY LTD

F-star develops bispecific antibody products to improve the treatment of serious diseases. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody.

www.f-star.com

GEN2 NEUROSCIENCE

IMMUNOBIOLOGY LTD

ImmunoBiology Limited (ImmBio) is a biotechnology company developing the next generation of vaccines for the prevention and treatment of infectious diseases by applying its proprietary HspC™ vaccine technology platform to development of breakthrough products.

www.immbio.com

KYMAB LTD

Kymab is using embryonic stem cell technology to develop its Kymouse™ platform, which encompasses the entire diversity of the B lymphocyte component of the human immune system. This will allow the discovery of highly selective, potent and well-tolerated monoclonal antibody-based biopharmaceuticals.

www.kymab.com

MEDICAL RESEARCH COUNCIL (MRC)

The Medical Research Council (MRC) improves the health of people in the UK - and around the world - by supporting excellent science, and training the very best scientists. We are a non-departmental public body funded through the government’s science and research budget.

www.mrc.ac.uk

Medicxi Ventures

Medicxi is a life sciences-focused investment firm, originally created at Index Ventures, a leading international venture capital firm with offices in London, San Francisco, Geneva, and St. Helier (Jersey).

www.medicxi.com

MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small molecule and biologic prescription medicines.

www.medimmune.com

Methuselah Health UK

Methuselah Health UK Limited is a drug discovery company founded in 2015 by Index Ventures to study the role of proteome instability in a number of human diseases linked to ageing.

www.methuselah-health.com

Mission Therapeutics Ltd

Mission Therapeutics is a private drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancers, neurodegenerative and other diseases.

www.missiontherapeutics.com

Morphogen-IX

MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins as a novel therapy for the treatment for pulmonary arterial hypertension.

www.morphogen-ix.com

Mote Research

Mote Research is committed to the development and application of a new generation of tools for genome editing in humans.

www.mote.co.uk

Nemesis Bioscience Ltd

Nemesis Bioscience has designed, and is developing, pioneering technologies that will resurrect anti-microbial therapies made ineffective by increasing microbial resistance. These unique therapeutics will impact one of the world's most significant clinical problems by not only treating antibiotic resistant infections, but also by preventing them in susceptible patients.

www.nemesisbio.com

Neophore Ltd

www.neophore.com

New Path Molecular

New Path Molecular specialises in the chemical synthesis of complex functional molecules using the cutting edge techniques, methods and instrumentation developed in the laboratories of Prof Steve Ley at the University of Cambridge. Our processes and molecules are being used to validate biological processes and produce products globally.

www.newpathmolecular.com

NORR

www.norr.com

Novogene

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world.

en.novogene.com

Oppilotech Ltd

Oppilotech are utilising systems biology and machine learning to build computational model of cells. The company is initially focusing on modelling bacteria (E. coli). The model is utilised to find viable first-in-class drug targets.

www.oppilotech.com

Phoremost Ltd

PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new 'druggable' target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel 'targeted' therapies more efficiently to market and pass these cost savings onto patients.

www.phoremost.com

PolyProx

PolyProx uses novel engineered proteins to trigger the cell's degradation machineries for new therapies in cancer and other diseases.

PredictImmune Limited

Providing tools to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.

www.predictimmune.com

RxCelerate Ltd

RxCelerate is an out-sourced drug development company, delivering complete preclinical drug development programmes and project management for virtual and semi-virtual companies.

www.rxcelerate.com

SomaNautix

Focussed on oncology product development for rare tumours, we have two major pipeline programmes. Products are being developed using our proprietary PolyNaut™ technology which delivers high therapeutic concentrations intracellularly to target cells through endocytosis and can also be functionalised with ligands to efficiently cross the blood brain barrier (BBB).

ww.somanautix.com

Sphere Fluidics Ltd

Sphere Fluidics has developed a new technology platform for single cell analysis and characterisation which enables the discovery and development of new biopharmaceuticals and novel ways to study single cell diseases, e.g. cancer.

www.spherefluidics.com

Stemnovate Limited

www.stemnovate.co.uk

Storm Therapeutics

STORM Therapeutics is a University of Cambridge spin-out, translating the ground breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of small molecule drugs to treat cancer and other diseases.

www.stormtherapeutics.com

Talisman Therapeutics

Talisman Therapeutics Ltd is a human stem cell drug discovery company. We are committed to revolutionising the discovery of treatments for Alzheimer's disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and relevant compound identification, which significantly accelerate drug discovery.

www.talisman-therapeutics.com

The Cambridge Partnership

The Cambridge Partnership (TCP) offers a company management service, specifically tailored for biotech companies, that takes care of routine corporate affairs, financial control and administration.

www.thecambridgepartnership.com

The Foundation Institute for 21st Century Medicine (C21Med)

This is where the concepts behind a number of technologies destined to shape medicine in the 21st Century have been born.

www.c21med.com

Total Scientific Ltd

Total Scientific is a contract research organisation with experience in all aspects of biomarker research, from identification of the biomarker using 'omics technology through independent assay design, development, optimisation and validation to multi-site clinical studies designed to validate or test biomarkers.

www.totalscientific.com

Z Factor

Z Factor Limited is a drug discovery company seeking novel therapeutic agents to treat alpha-1-antitrypsin (A1AT) deficiency. A1AT deficiency is a genetic disorder that affects around 1 in 2,000 people.

Campus